Specialty Pharmacy

This drug was previously approved, in 2017, to treat HCV in adults.

The preclinical data was presented by Beam Therapeutics, Monday at the American Society of Gene and Cell Therapy (ASGCT) 22nd Annual Meeting in Washington, DC.

Study finds cannabidiol may act as a Trojan horse to transport molecules into the brain.

Experts emphasized the need for clinicians to use every available tool when patients need PCSK9 inhibitors but face access barriers.

During a session on Monday at Asembia’s Specialty Pharmacy Summit 2019, experts discussed specialty pharmacy’s potential to improve outcomes for patients with pulmonary arterial hypertension.

Diagnostic delay tends to be a challenge for patients with hereditary angioedema, a rare but serious condition affecting 1 in 50,000 individuals.

During the week of the summit, you’ll find shows unique to the city that are sure to make lifelong memories.

Alison Duffy, PharmD, BCOP, from UM Greenebaum Comprehensive Cancer Center, talks about some of the emerging agents in the chronic lymphocytic leukemia treatment landscape.

This new offering provides an end-to-end digital prescription process with nationwide access through more than 25,000 retail pharmacies.

Study demonstrates safety of oral immunotherapy for peanut allergy in large group of preschool-aged children.

Lisa Holle, PharmD, BCOP, FHOPA, associate clinical professor at the University of Connecticut discusses the evolving role of genomics in the treatment of prostate cancer.

Check back daily for our coverage of the Asembia Specialty Pharmacy Summit this week.

Adults who experience a heart attack or stroke have an approximately 1 in t3 chance to have another cardiovascular event.

This is the first time that the FDA has approved a treatment for pediatric patients with SLE. Belimumab has been approved for use in adult patients since 2011. GSK’s application for belimumab use in pediatric patients was granted the FDA’s Priority Review designation.

Samsung Bioepis’ etanercept-ykro (Eticovo) was approved to treat all of the indications of the reference product, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

The COAST-X clinical trial program is evaluating ixekizumab across various population subsets of patients with axial spondyloarthritis.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

An analysis showed increasing rates of medical marijuana use for individuals diagnosed with cancer over a 10-year period.

Investigators used a CRISPR technique to expose weaknesses in the acute myeloid leukemia enzyme that many drugs target.

Announcement positions specialty pharmacy group for continued growth.

Top news of the day from across the health care landscape.

Risankizumab-rzaa (Skyrizi, AbbVie) is indicated for adults with moderate-to-severe plaque psoriasis who are candidates for systemic or phototherapy.

The combination of selinexor and 4-OHT may be able to prevent endocrine resistance in hormone-responsive breast cancer by rewiring gene pathways.

Top news of the day from across the health care landscape.

Research investigates whether statins are safe and effective for patients with inflammatory conditions, such as rheumatoid arthritis.

The potential for prescription drugs to cost more than $1 million for a treatment regimen creates a mixed bag of conundrums for the health care system.

Research investigates cytomegalovirus to understand the process of targeting HIV in order to eradicate it from the body.